Cash, cash equivalents and investments as of September 30, 2025, were $143.7 million. Monopar expects that its current funds will be sufficient to continue operations at least through December 31, 2027, in order to: assemble a regulatory package and file an NDA for the ALXN1840 investigational drug candidate for Wilson disease; continue to conduct and conclude our first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr, continue to conduct our first-in-human therapeutic clinical trial of MNPR-101-Lu, and advance our preclinical MNPR-101-Ac program into the clinic; and invest in internal R&D projects to expand radiopharmaceutical pipeline.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data
- Coinbase upgraded, Six Flags downgraded: Wall Street’s top analyst calls
- Monopar Therapeutics Unveils Promising Phase 2 Study Results
- Monopar Therapeutics initiated with an Outperform at Leerink
- Monopar presents new data, analyses from Phase 2 ALXN1840-WD-204 study